13F Insight
DOSSIER · 13F-HR · Q2 2026

Versant Venture Management, LLC

$163M in tracked AUM across 8 positions as of Q2 2026.

VV
CIK 0001560009 · last filed Jun 30, 2026
Total AUM
$163M
as of Q2 2026
Holdings
8
—
positions
Whale Score
71
71
strong
Activity
—
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Versant Venture Management, LLC 13F Filing
Portfolio Overview

Versant Venture Management, LLC reported a significant expansion in its 13F portfolio for the period ending September 30, 2025. The total portfolio value surged by 137.0%, rising from $82.14M in the previous quarter to $194.63M. This substantial increase in assets under management (AUM) was driven almost entirely by a single new capital allocation rather than broad market appreciation. The p...

Key Holdings

The portfolio is dominated by a "barbell" structure, with the top two positions comprising over 85% of the total assets.

  • Lenz Therapeutics, Inc. (63.59%): This is the standout position in the portfolio, valued at $123.76M. As a new position, it represents a massive bet on a single company. With 2.66M shares held, this allocation dictates the performance of the entire fund for the quarter.
  • Monte Rosa Therapeutics, Inc. (21.52%): The second-largest holding remains significant at $41.89M (5.65M shares). The fact that this position was "unchanged" during a quarter where the firm added over $100M in new capital suggests Versant is maintaining a distinct separation between this existing core holding and the new Lenz allocation.
  • CRISPR Therapeutics AG (4.96%): Once a major component of the portfolio, this position has been reduced significantly to $9.65M (149K shares). It now serves as a minor satellite position compared to the top two holdings.
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
GLUE
Monte Rosa Therapeutics, Inc.
$77M3.2M47.3%02
IPSC
Century Therapeutics, Inc.
$30M12.2M18.3%03
JBIO
Jade Biosciences, Inc.
$22M992K13.6%04
LENZ
Lenz Therapeutics, Inc.
$15M2.7M9.3%05
CTNM
Contineum Therapeutics, Inc.
$9M543K5.5%06
H17182108
CRISPR Therapeutics AG
$8M149K5.0%07
SKYE
Skye Bioscience, Inc.
$1M2.0M0.9%08
OVASUSD
Tempest Therapeutics, Inc.
$299K270K0.2%

Filing history

2026Q2Jun 30
$163M▲ 15.0%
8 positionsView →2026Q1Mar 31
$141M▼ 6.4%
8 positionsView →2025Q4Dec 31
$151M▼ 22.4%
7 positionsView →2025Q3Sep 30
$195M▲ 137.0%
7 positionsView →2025Q2Jun 30
$82M▲ 42.6%
8 positionsLocked2025Q1Mar 31
$58M▼ 33.6%
6 positionsLocked2024Q4Dec 31
$87M▲ 36.5%
7 positionsLocked2024Q3Sep 30
$64M▼ 17.8%
6 positionsLocked2024Q2Jun 30
$77M▼ 25.1%
8 positionsLocked2024Q1Mar 31
$103M▼ 73.5%
7 positionsLocked2023Q4Dec 31
$389M▲ 106.7%
7 positionsLocked2023Q3Sep 30
$188M▲ 123.2%
8 positionsLocked
Showing 12 of 44